The significance of ultra-low EGFR T790M mutations on EGFR-TKI efficacy in patients with NSCLC -the WJOG13119L study

被引：0

作者：

Masuda, Takeshi ^{[1
]}

Miura, Satoru ^{[2
]}

Koso, Hidenori ^{[3
]}

Yanagihara, Kazuhiro ^{[4
]}

Okamoto, Tatsuro ^{[5
]}

Shoda, Hiroyasu ^{[6
]}

Shimizu, Junichi ^{[7
]}

Kanaji, Nobuhiro ^{[8
]}

Hara, Satoshi ^{[9
]}

Sakata, Shinya ^{[10
]}

Tokito, Takaaki ^{[11
]}

Kashiwabara, Kosuke ^{[12
]}

Nishikawa, Kazuo ^{[13
]}

Watanabe, Hiroshi ^{[14
]}

Maeno, Ken ^{[15
]}

Suzuki, Shigeki ^{[16
]}

Hayakawa, Daisuke ^{[17
]}

Yamamoto, Nobuyuki ^{[18
]}

Nakagawa, Kazuhiko ^{[19
]}

Noboru, Hattori ^{[1
]}

机构：

[1] Hiroshima Univ Hosp, Dept Resp Med, Hiroshima, Japan

[2] Niigata Canc Ctr Hosp, Dept Internal Med, Niigata, Japan

[3] Natl Hosp Org, Oita Med Ctr, Dept Surg, Oita, Japan

[4] Kansai Elect Power Hosp, Dept Med Oncol, Osaka, Japan

[5] Natl Hosp Org Kyushu Canc Ctr, Dept Thorac Oncol, Fukuoka, Japan

[6] Hiroshima City Hiroshima Citizens Hosp, Dept Resp Med, Hiroshima, Japan

[7] Aichi Canc Ctr Hosp, Dept Thorac Oncol, Nagoya, Aichi, Japan

[8] Kagawa Univ, Dept Internal Med, Div Hematol Rheumatol & Resp Med, Fac Med, Takamatsu, Kagawa, Japan

[9] Itami City Hosp, Dept Resp Med, Itami, Hyogo, Japan

[10] Kumamoto Univ Hosp, Dept Resp Med, Kumamoto, Japan

[11] Kurume Univ, Div Respirol Neurol & Rheumatol, Dept Internal Med, Sch Med, Kurume, Fukuoka, Japan

[12] Kumamoto Reg Med Ctr, Dept Resp Med, Kumamoto, Japan

[13] Oita Univ, Fac Med, Dept Med Oncol & Hematol, Oita, Japan

[14] Saka Gen Hosp, Dept Resp Med, Shiogama, Japan

[15] Nagoya City Univ, Dept Resp Med Allergy & Clin Immunol, Grad Sch Med Sci, Nagoya, Aichi, Japan

[16] Sagamihara Kyodo Hosp, Dept Gen Thorac Surg, Sagamihara, Kanagawa, Japan

[17] Juntendo Univ, Fac Med, Dept Resp Med, Tokyo, Japan

[18] Wakayama Med Univ, Dept Internal Med 3, Wakayama, Japan

[19] Kindai Univ, Fac Med, Dept Med Oncol, Higashiosaka, Osaka, Japan

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷

关键词：

D O I：

10.1016/j.annonc.2022.05.028

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

O6-3

引用

页码：S470 / S471

页数：2

共 50 条

[1] The significance of micro-EGFR T790M mutation on EGFR-TKI efficacy in patients with NSCLC: The WJOG13119L study.
Sato, Yuki
Masuda, Takeshi
Miura, Satoru
Tachihara, Motoko
Hosokawa, Shinobu
Nakamura, Atsushi
Miyawaki, Taichi
Yoshimine, Kohei
Mori, Masahide
Shiraishi, Hideaki
Hamai, Kosuke
Haratani, Koji
Maeda, Sumiko
Tabata, Eriko
Kitagawa, Chiyoe
Tanizaki, Junko
Imai, Takumi
Yamamoto, Nobuyuki
Nakagawa, Kazuhiko
Hattori, Noboru
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[2] T790M MUTATION ASSOCIATED WITH BETTER EFFICACY OF CONTINUOUS EGFR-TKI TREATMENT IN ADVANCED NSCLC PATIENTS WITH ACQUIRED RESISTANCE TO EGFR-TKI
Ren, Shengxiang
Li, Wei
Li, Aiwu
Chen, Xiaoxia
Gao, Guanghui
He, Yayi
Li, Xuefei
Zhou, Caicun
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1084 - S1084
[3] Detection of the T790M Mutation of EGFR in Plasma of Advanced NSCLC Patients with Acquired Resistance to EGFR-TKI (WJOG8014LTR)
Azuma, Koichi
Takahama, Takayuki
Sakai, Kazuko
Takeda, Masayuki
Hida, Toyoaki
Hirabayashi, Masataka
Oguri, Tetsuya
Tanaka, Hiroshi
Ebi, Noriyuki
Sawa, Toshiyuki
Bessho, Akihiro
Tachihara, Motoko
Akamatsu, Hiroaki
Bandoh, Shuji
Himeji, Daisuke
Ohira, Tatsuo
Shimokawa, Mototsugu
Yamamoto, Nobuyuki
Nakanishi, Yoichi
Nakagawa, Kazuhiko
Nishio, Kazuto
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S389 - S390
[4] Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC
Yang, Shuo
Mao, Shiqi
Li, Xuefei
Zhao, Chao
Liu, Qian
Yu, Xiaofei
Wang, Yan
Liu, Yiwei
Pan, Yingying
Wang, Chunyan
Gao, Guanghui
Li, Wei
Xiong, Anwen
Chen, Bin
Sun, Hui
He, Yayi
Wu, Fengying
Chen, Xiaoxia
Su, Chunxia
Ren, Shengxiang
Zhou, Caicun
LUNG CANCER, 2020, 139 : 133 - 139
[5] Characterization of T790M According to Primary EGFR Mutation in Post EGFR-TKI Progression NSCLC in Brazil
Ferreira, C.
Zalis, M.
Custodio, M.
Montenegro, G.
Zukin, M.
Mathias, C.
Haddad, C.
Mascarenhas, E.
Araujo, L.
Montella, T.
Da Silva, B.
Bustamante, C.
Muras, A.
Reis, M.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S158 - S158
[6] T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients
Li, Wei
Ren, Shengxiang
Li, Jiayu
Li, Aiwu
Fan, Lihong
Li, Xuefei
Zhao, Cao
He, Yayi
Gao, Guanghui
Chen, Xiaoxia
Li, Shuai
Shi, Jingyun
Zhou, Caicun
Fei, Ke
Schmid-Bindert, Gerald
LUNG CANCER, 2014, 84 (03) : 295 - 300
[7] The Clinical Usefulness of Liquid Biopsy for Detection and Dynamic Monitoring of EGFR T790M in NSCLC Patients on EGFR-TKI Therapy
Szpechcinski, A.
Duk, K.
Bryl, M.
Czyzewicz, G.
Wojda, E.
Florczuk, M.
Sliwinski, P.
Barinow-Wojewodzki, A.
Chorostowska-Wynimko, J.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S803 - S803
[8] Osimertinib for EGFR-Mutant NSCLC Patients With Acquired T790M and EGFR Amplification After First-Generation EGFR-TKI Resistance
Zhang, Yidan
Xu, Yingqi
Xu, Jianlin
Zhong, Hua
Xia, Jinjing
Zhong, Runbo
CANCER SCIENCE, 2024,
[9] A Comparison of ddPCR and ARMS for Detecting EGFR T790M Status from Advanced NSCLC Patients with Acquired EGFR-TKI Resistance
Wang, Wenxian
Song, Zhengbo
Zhang, Yiping
Jin, Ying
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1211 - S1211
[10] Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance
D. Zheng
X. Ye
M. Z. Zhang
Y. Sun
J. Y. Wang
J. Ni
H. P. Zhang
L. Zhang
J. Luo
J. Zhang
L. Tang
B. Su
G. Chen
G. Zhu
Y. Gu
J. F. Xu
Scientific Reports, 6

← 1 2 3 4 5 →